Delivery Order SPE2DB22D3004-SPE2DB25FRB36
Award Date
6/12/25
Potential Completion Date
6/13/25
Potential Value
$1.3K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is a delivery order valued at $1,263.72 awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, with a completion date of May 22, 2025. This contract is not set aside and was competitively awarded. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award, valued at $1,263.72, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. The contract is a delivery order with a firm fixed price, and the ultimate completion date is March 10, 2025. This contract does not have a set-aside designation, indicating open competition. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions...
This federal contract award to Amerisourcebergen Drug Corp is a $5,126.16 delivery order for the product HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. The contract has an ultimate completion date of August 26, 2024 and was awarded on August 23, 2024. The contract is a firm fixed price arrangement with the Defense Logistics Agency (DLA), a defense agency within the Department of Defense. Amerisourcebergen is a major pharmaceutical distributor and healthcare solutions provider that plays a critical role...
This federal contract award to Amerisourcebergen Drug Corp is for the pharmaceutical product HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. The $113,657.00 firm fixed price delivery order was awarded by the Defense Logistics Agency (DLA), a defense agency. The contract has an ultimate completion date of May 22, 2025 and is not set aside. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that serves as a critical supplier of medical and pharmaceutical products to federal agencies,...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $97,545.40, is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. This is a firm fixed-price delivery order contract with a completion date of February 28, 2025. The contract was awarded on February 27, 2025 and does not have a set-aside designation, indicating open...
This federal contract award is for the delivery of the pharmaceutical product HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML to the Defense Logistics Agency (DLA). The fixed-price delivery order, valued at $8,856.30, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on May 14, 2025. The contract has an ultimate completion date of May 15, 2025 and is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,263.72 firm fixed price delivery order is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product. The contract has an ultimate completion date of March 21, 2025. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
This federal contract award, valued at $5,276.38, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The award is a delivery order contract for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. The contract has an ultimate completion date of July 9, 2024 and is a firm fixed price agreement. This award is not associated with a set-aside designation. Amerisourcebergen Drug Corp, a major supplier of pharmaceutical...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the leading global pharmaceutical distributor Amerisourcebergen Corporation. The $27,996.72 contract is for the supply of the pharmaceutical product HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, with a completion date of March 4, 2024. Amerisourcebergen Drug Corp, a for-profit organization, serves as a prime contractor providing a wide range of pharmaceutical products...
The Defense Logistics Agency (DLA) awarded a $9,463.68 firm-fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. This order is a part of AmerisourceBergen's larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract has no set-aside designation, indicating...